Generic Nitrostat Launched
August 29, 2016 –The launch of A-rated generics to Pfizer’s Nitrostat® (Nitroglycerin) sublingual tablets was announced by Dr. Reddy’s. Nitrostat sublingual tablets are indicated in the treatment and prevention of chest pain (angina pectoris) due to coronary artery disease. Dr. Reddy’s nitroglycerin sublingual tablets are available in 0.3mg, 0.4mg and 0.6mg strengths. According to IMS Health, Nitrostat had U.S. sales of approximately $108 million for twelve months ending in March 2016.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.